Fresenius Medical Care AG & Co. KGaA — FDA Warning Letter, 2026-08-25: CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
On August 25, 2026, FDA Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-119 to Fresenius Medical Care AG & Co. KGaA regarding CGMP violations at Fresenius USA Manufacturing, Inc.'s Ogden, Utah facility (FEI 1713747), inspected March 2–6, 2026. The FDA identified failures to investigate customer complaints and batch discrepancies for Delflex Peritoneal Dialysis Solution LVP bags, including a trend of 35 complaints covering ~156 bags in August 2025 attributed to printing-caused holes; Fresenius initially assigned lowest severity despite its own risk matrix flagging peritonitis as potential harm at highest severity, and did not recall until April 2026 post-inspection, exposing dialysis patients to non-sterile product contamination risk. FDA directed Fresenius to provide independent root-cause analysis of leaking bags including failure mode analysis, printing control review, alternative printing technology assessment, and corrective actions, plus comprehensive quality unit assessment and remediation.
Argus analysis
# FDA Warning Letter Analysis: Fresenius Medical Care AG & Co. KGaA
**Company and Violations**
On August 25, 2026, the FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter to Fresenius Medical Care AG & Co. KGaA regarding its Ogden, Utah manufacturing facility (FEI 1713747). The inspection, conducted March 2–6, 2026, identified significant Current Good Manufacturing Practice (CGMP) violations in the production of finished pharmaceuticals. The FDA determined that Fresenius's drug products are adulterated because the firm's manufacturing methods, facilities, and controls fail to meet regulatory standards.
**Regulatory Citations**
The violations centered on 21 CFR parts 210 and 211, which establish CGMP requirements. The primary citation, 21 CFR 211.192, requires thorough investigation of any batch discrepancy or specification failure. A secondary citation, 21 CFR 211.100(a), mandates adequate written procedures ensuring products possess their represented identity, strength, quality, and purity. These regulations mean manufacturers must systematically investigate quality issues, implement corrective actions, and maintain robust quality oversight—not rely on end users to detect defects. The warning letter specifically documents Fresenius's inadequate response to a trend of leaking Delflex Peritoneal Dialysis Solution bags discovered in August 2025, which posed peritonitis risk to patients using non-sterile solutions.
**Expected Next Steps**
Fresenius must submit a comprehensive written response addressing root-cause analysis of leaking bags, quality unit authority and resources, investigation procedures, statistical process controls, equipment qualification, and visual inspection protocols. Industry observers should monitor whether the company initiates product recalls, implements manufacturing process changes (particularly printing technology), engages independent assessments, and demonstrates sustained quality improvements. Failure to adequately respond may trigger FDA enforcement action, including product seizures or facility closure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Fresenius Medical Care AG & Co. KGaA MARCS-CMS 730319 — August 25, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-119 Product: Drugs Recipient: Recipient Name Ms. Helen Giza Recipient Title Chief Executive Officer Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d. Höhe Germany (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-119 August 25, 2026 Dear Ms. Giza: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fresenius USA Manufacturing, Inc. dba Fresenius Medical Care North America Ogden Plant, FEI 1713747, at 475 W. 13th St., Ogden, Utah, from March 2 to 6, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigator observed specific violations including, but not limited to, the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). You failed to adequately investigate customer complaints for the large volume parenteral (LVP) bag drug products you manufacture. Your investigations were not thorough and did not appropriately evaluate the risk to product quality. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs). Specifically, in August 2025 you initiated an investigation due to a complaint trend for leaking bags of Delflex Peritoneal Dialysis Solution. This investigation noted that you eventually received 35 complaints covering approximately 156 bags from multiple batches. Your investigation attributed the bag leaks “to holes caused by printing.” Despite your Risk Management Matrix indicating peritonitis as a potential harm and recommending the highest severity level, you instead assigned the lowest severity level with the potential harm being “damage of property.” Although you ultimately conducted a recall in April 2026 after our inspection, you chose not to conduct a recall following the results of your August 2025 investigation. Your justifications for these decisions included: the lack of attributable peritonitis cases, product labelin…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Fresenius Medical Care AG & Co. KGaA had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Fresenius Medical Care AG & Co. KGaA as of 2026-09-01. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Fresenius Medical Care AG & Co. KGaA — FDA Warning Letter, 2026-08-25: CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-fresenius-medical-care-ag-and-co-kgaa-2026-08-25-cgmp
"Fresenius Medical Care AG & Co. KGaA — FDA Warning Letter, 2026-08-25: CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-fresenius-medical-care-ag-and-co-kgaa-2026-08-25-cgmp.
Argus HQ Research. "Fresenius Medical Care AG & Co. KGaA — FDA Warning Letter, 2026-08-25: CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-fresenius-medical-care-ag-and-co-kgaa-2026-08-25-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_fresenius_medical_care_ag_and_co_kgaa_2026_08_25_cgmp_2026,
title = {Fresenius Medical Care AG & Co. KGaA — FDA Warning Letter, 2026-08-25: CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-fresenius-medical-care-ag-and-co-kgaa-2026-08-25-cgmp},
note = {Accessed: September 2, 2026}
}